Friday, 15 November 2019

Enema Based Products Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Market Research Future has recently declared the addition of a New Research Study to its thorough collection of Research Reports “Global Enema Based Products Market Research Report - Forecast To 2023”.
The global enema based products market is expected to show sharp growth over the forecast period. Rising prevalence of gastrointestinal disorders such as constipation across the globe, availability of various types of enema administration kits such as cleansing and carminative enema and overall demand for enema administration products drivers the market growth.
Enema based products are used to remove waste for the rectum and can be used at home as a remedial measure for constipation and other gastrointestinal disorders. Constipation is a major gastrointestinal condition, found to be prevalent across the globe. Other condition that may require enema administration are obesity, diabetes, and cancer.
Risk involved in the use of enema based product is irritation in the rectum and embolism, in case of incorrect use of enema administration
According to the latest 2016 data from the World Health Organization, an estimated 422 million adults were living with diabetes mellitus across the globe.
The global enema based products market is expected to grow at a CAGR of 10.2% during the forecast period.
Key Players
Some of the key players in this market are Baxter International, Inc. (U.S), MacoPharma (U.K),  Hollister Incorporated  (U.S), Coloplast Group (Germany), Medline Industries, Inc. (U.S), and B Braun Melsungen AG (Germany).
Segments
The global enema based products market is segmented on the basis of administration type, indication, preparation, and end users.
On the basis of administration type, market is segmented into cleansing enema, carminative enema, retention enema, return-flow enema, and others. Cleansing enema is further segmented into large volume enema, small volume enema, and prepackaged disposable enema. Retention enema is further segmented into oil enema, sedative enema, nutrient enema, anesthetic enema, medicinal enema, and others.
On the basis of indication, the market is market is segmented into constipation, diarrhea, obesity, cancer and others.
On the basis of preparation, the market is divided into sodium phosphate enemas, coffee enemas, barium enemas, water-soluble contrast enemas and others.  Barium enemas is further segmented into single-column barium enema and double-contrast barium enema.
On the basis of end user, the market is divided into hospitals or clinics, home, and others. 
Regional Analysis
The global enema based products market is segmented into regions namely Americas, Europe, Asia Pacific and the Middle East & Africa. America is the largest market for enema based products owing to increasing use of enema based products at home, and rising demand for enema kits by healthcare providers. According to the Canadian Journal of Gastroenterology, constipation is a common problem among the people in the North American region. One of the study stated that the 20% of the North American population suffer from constipation.
Europe is the second largest market owing rise in the number of enema administration procedures in the hospitals. Rising prevalence of constipation, diarrhea, and obesity also contributes to the progress of the market. Prevalence of diabetes is also found to be increasing in the Europe. According to the World Health Organization, nearly 60 million people with diabetes in the European Region and the prevalence is higher among people aging 25 years and above.
In Asia Pacific, the prevalence of chronic diseases such as diabetes and obesity is found to be increasing. Diabetes is one of the major problem in China and India. India has world’s second largest population of diabetic patients, around 69.2 million in 2015 and that are expected to increase to 123.5 million by 2040. The number of undiagnosed diabetes is higher in India which was around 36 million in 2015.
The Middle East & Africa also shows a steady rise in the market owing to lack of physical exercise, increasing problem of constipation and availability of enema based products in the market.
Avail the in-depth table of content TOC & market Segmented By Administration (Cleansing, Carminative, Retention, and Return-Flow), By Indication (Constipation, Diarrhea, Obesity), By Preparation (Sodium Phosphate, Coffee), and By End User (Hospitals, Homecare) @ https://www.marketresearchfuture.com/reports/enema-based-products-market-4370  
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Pediatric Brain Tumor Market size and Key Trends in terms of volume and value 2019

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Pediatric Brain Tumor Market Research Report - Global Forecast till 2023” Gives industry size, top players and worldwide demand
Key Players for Global Pediatric Brain Tumor Market:
Some of the key players in this market are: Abbott. (US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US) , Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and others
Pediatric brain tumor is uncontrolled or abnormal growth of normal cell in the brain in children. Brain tumors mainly are of two types, cancerous (malignant) and noncancerous (benign). It is second most common type of cancer in children and it comprise about 25% of childhood cancer.
The cases of pediatric tumors are increasing globally that leading the growth of the market. Advanced diagnostic technology and new treatments are also major driving forces of the market. Rising healthcare infrastructure, extended insurance cover, government initiatives, and emerging economies are driving the market. Rising funding for R&D and clinical trials as well as FDA approvals are also major growth factors for global pediatric brain tumor market.
Segmentation:
Global pediatric brain tumor market has been segmented on the basis of types which comprises of gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, non-neuroepithelial tissue tumors, meningeal tumors, and others. Gliomas is further sub-segmented into astrocytoma, malignant gliomas, and others. Mixed neuronal-glial tumors are further sub-segmented into ganglioglioma, subependymal giant cell tumor, pleomorphic xanthoastrocytoma, and others. Embryonal tumors are further sub-segmented into primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Tumors arising from non-neuroepithelial tissue are further sub-segmented into craniopharyngioma, pineal region tumors, and others.
On the basis of diagnosis, it is segmented into physical exam, Imaging tests, brain or spinal cord tumor biopsy, Llmbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Angiogram, and others. Magnetic Resonance Imaging (MRI) scan is further sub-segmented into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic resonance perfusion, Functional MRI (fMRI), and others. Brain or spinal cord tumor biopsy is further sub-segmented into Stereotactic needle biopsy, Craniotomy, and other.
On the basis of treatment, the market has been segmented into surgery, therapies, drug treatment, and others. Surgery is further sub-segmented into surgical biopsy, resection (removal), Shunt placement/revision, and others. Therapies includes Radiation therapy, Chemotherapy, Targeted therapy, and others. Chemotherapy includes Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, Lomustine (CCNU), Methotrexate, Temozolomide, Thiotepa, Vincristine, and others. Drug treatment is further sub-segmented into Corticosteroids, Anti-seizure drugs (anti-epileptics), Hormones, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Browse Complete 76 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented By Types (Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, and others), By Diagnosis (Imaging Tests, Brain Or Spinal Cord Tumor Biopsy, and others), By Treatment, By End User @ https://www.marketresearchfuture.com/reports/pediatric-brain-tumor-market-3690
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Carcinoid Syndrome Management Market to show steady growth, 2019

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Carcinoid Syndrome Management Market Research Report- Global Forecast To 2022” Gives industry size, top players and worldwide demand
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Segmentation:
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented intochemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Key players
  • Novartis International AG (Sandoz)
  • Pharmascience Inc.
  • Omega Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Biopharmaceuticals, Inc.
  • Sirtex Medical Limited
  • BTG International Ltd.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Limited
Study Objectives:
  • To provide detail analysis of parent market and the changing market dynamics of the industry.
  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.
  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.
  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.
Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by organs affected (Small Intestine, Lungs, Rectum, Appendix, Colon, Stomach, Pancreas, Liver and others) by Treatment (Chemotherapy, Biological therapy, and Hepatic Artery Embolization Agents), by End users (Hospital, Clinics, Cancer institute and treatment centers) @ https://www.marketresearchfuture.com/reports/carcinoid-syndrome-management-market-2843
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Anti-Viral Drugs Market Segments, Opportunity, Growth and Forecast by End-use Industry 2019

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Global Osteoporosis Drugs Market Research Report - Forecast to 2022” Gives industry size, top players and worldwide demand
The Global Osteoporosis Market is currently eyeing for a staggering USD 14,300 million valuation during the forecast period (2013-2022), claims Market Research Future (MRFR) in a detailed study. Booming urbanization and technological advancements may have a lot to do with the progressing world, but they have some adverse effects too. Osteoporosis is one such side-effect of the fast-evolving lifestyle and the inflating osteoporosis drugs market is a direct result of that. The market is about to witness a moderate CAGR of 4.7% during the forecast period.
The Osteoporosis Drugs market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.
The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.
Key Players:
  • Eli Lilly and Company
  • Merck & Co.
  • Novartis International AG
  • Amgen Inc.
  • Hoffmann La Roche Ltd.
  • Pfizer Inc.
  • Novo Nordisk
  • Teva Pharmaceutical Industries Ltd
Segmentation:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.
Regional Analysis
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
Browse Premium Research Report with Tables of Contents Segmented by drug class (Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH) and Others), by route of administration (oral, injectable and others) and by gender (male and female) @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Latest Study Offers Detailed Insights on Anti-Viral Drugs Market 2019

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Global Anti-Viral Drugs Market Research Report- Forecast to 2022” Gives industry size, top players and worldwide demand
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase ainhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 
Key Players
MRFR have enlisted some of the prominent companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by application (hepatitis, HIV/AIDS, herpes, influenza and others) and by mechanism of action (nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others) @  https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cleanroom Technology Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Market Scenario:
The growing biotechnology sector is likely to be a major driver for the global cleanroom technology market over the forecast period. Biotechnology research and product development require a complete absence of potential contaminants, as even the smallest presence of contaminants can ruin the results of the research or product development efforts. The growing life sciences sector has driven investment in the biotechnology sector in recent years, as disease treatment and other application avenues have come in sharp focus. Increasing government support to the life sciences sector is likely to be the major driver for the global cleanroom technology market over the forecast period.
Cleanroom is basically a controlled environment which has low level of pollutants such as air-born microbes and particles, dust, aerosols which contaminate the surrounding area. Cleanroom technology is used by nearly all the industries in order to avoid the adverse effects caused by the air pollutants and small particles in the manufacturing process of a product. Globally the market for cleanroom technology is growing rapidly. Globally the market for cleanroom technology is expected to show an exponential growth and would reach approximately $4 Billion in 2022.
The increasing pharmaceutical industry is also likely to be a major contributor to the global cleanroom technology market. Increasing efforts to come up with more efficient and effective pharmaceutical formulations are likely to lead to increasing demand from the cleanroom technology market over the forecast period. Other industries are also making increasing use of cleanroom technology in order to enhance the manufacturing process, which is likely to drive the global cleanroom technology market at a strong growth rate over the forecast period.
Key Players    
  • Alpiq Group,
  • Ardmac Ltd,
  • Camfil,
  • Clean Air Products,
  • Helapet Limited,
  • M+W Group GmbH,
  • Nicomac Srl,
  • Royal Imtech N.V.,
  • Simplex Isolation Systems,
  • Taikisha Ltd. and others.
Segmentation:
The global cleanroom technology market is segmented on the basis of equipment, consumable, end user, and region.
The cleanroom technology market has been segmented on the basis of equipment into laminar air flow, HEPA filters, cleanroom air showers, cleanroom filters, desiccator cabinets, particle counters, cleanroom pass through systems, environmental monitoring system, and others.
On the basis of consumables, the market is segmented into head-caps, gloves, face masks, lab suits, footwear, wipes, swabs, disinfectants, and others.
On the basis of end user, the cleanroom technology market is segmented into pharmaceutical industry, biotechnology industry, research laboratories, and others.
Regional Analysis
Globally Americas is the largest market for cleanroom technology. Europe is the second-largest market. Furthermore Asia-Pacific market is expected to be the fastest growing market for cleanroom technology.
The report for cleanroom technology market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by equipment (laminar air flow, HEPA filters, cleanroom air showers, cleanroom filters, desiccator cabinets, particle counters, cleanroom pass through systems, environmental monitoring system, and others), by consumables (head-caps, gloves, face masks, lab suits, footwear, wipes, swabs, disinfectants, and others) by end user (pharmaceutical industry, biotechnology industry, research laboratories, and others) @ https://www.marketresearchfuture.com/reports/cleanroom-technology-market-2169
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Immune Thrombocytopenia (ITP) Market 2019–By Identifying the Key Market Segments and Key players holding market share

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Immune Thrombocytopenia (ITP) Market Research Report - Forecast till 2023” Gives industry size, top players and worldwide demand
The Global Market for Immune Thrombocytopenia is projected to surpass a valuation of USD 2,300 Mn by 2023, reflecting a compound annual growth rate of 5.78% between 2018 and 2023. Rising prevalence of immune thrombocytopenia (ITP) worldwide has fueled the demand for ITP therapeutics. Increased government effort to improve healthcare infrastructure in countries such as India, China and Brazil has reflected favorably on the global ITP market. In addition, increased focus on development of novel drugs and therapeutics is also having a positive impact on the market. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP.
The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes.  A detail analysis of the various sub-markets across key region of the world is also available in the report.
Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market
Competitive Landscape:
CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.
Research Methodology:
The research methodology envelops the range and depth of markets and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.   
Segmental Analysis:
The segmental analysis of the global ITP market is based on type, treatment, end-user and region. By type, the market has been segmented into chronic immune thrombocytopenia and acute immune thrombocytopenia. In 2017, the chronic immune thrombocytopenia segment for 85% share of the global market. During the forecast period, the segment is projected to witness a CAGR of 5.94% and reach a valuation of USD 2,036.9 Mn. This can be attributed to factors such as rising incidence rates, approval of targeted treatments, increase in risk factors, use of prior medications, and increase occurrence of secondary hematological disorders.
On the basis of the treatment, the market has been segmented into intravenous immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and others.  In 2017, the corticosteroids segmented represented 40% share of the global ITP market in terms of value. The segment is likely to surge at a CAGR of 5.57% during the assessment period. Corticosteroids are a class of steroid hormones that are commonly used in ITP therapies.
On the basis of end-user, the market has been segmented into hospitals and clinics, specialty centers, research and academic institutes, and others. The hospitals & clinic segment currently commands for close to 38% market share and is projected to capture an impressive CAGR of 6.22% during the review period.
Regional Outlook: 
On the basis of region, the Global ITP market is segmented into Americas, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA). Of these, the Americas accounted for 43.3% market share in 2017. The Americas is expected to spearhead the global ITP market throughout the assessment period. This is primarily owing to the increasing prevalence rates coupled with the availability of treatment options and presence effective reimbursement policies. According to the National Organization for Rare Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the US is estimated to be 3.3 per 100,000 adults/year. In addition, Americas is expected to remain an important market for ITP during the assessment period. Americas is followed by Europe and Asia-Pacific respectively. In Europe, factors such as favorable government policies and high healthcare expenditure is supporting the growth of the market. At the same time, presence of advanced healthcare infrastructure is providing an impetus to the market in Europe. The region is likely to remain its second spot over 2023. In Asia Pacific, increased efforts towards improving healthcare services and rising level of awareness among people is anticipated to drive the market’s growth in APAC in the forthcoming years.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures Segmented by By Treatment (Intravenous immunoglobulins, Corticosteroids, Thrombopoietin receptor agonists, Others), By End-user (Hospitals and clinics, Specialty Centers, Research and Academic Institutes, others)
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)